The classical neurotransmitters dopamine, norepinephrine, epinephrine, histamine, and serotonin (5HT) are all transported by the neuronal isoform of the vesicular monoamine transporter (VMAT2) and are found in distinct classes of storage organelles in the central nervous system (CNS) (reviewed in refs 1, 2). These biogenic amines, with the exception of histamine, are also transported by the VMAT1 isoform, found only in neurohormone-containing large dense core vesicles (LDCV) in various endocrine and neuroendocrine cells. The vesicular acetylcholine (ACh) transporter (VAChT) is a third member of this transporter gene family and represents a single isoform expressed exclusively on small synaptic vesicles (SSV) in all cholinergic neurons (reviewed in ref 3) . These vesicular amine transporters share a similar structure and use similar bioenergetic mechanisms for substrate accumulation into secretory organelles. Various drugs specifically interact with these proteins and decrease transmitter levels in synaptic vesicles. Reserpine is a competitive antagonist of both VMAT isoforms, but once bound becomes occluded in the protein and irreversibly blocks transport, vesicular storage, and quantal release (4, 5) . Tetrabenazine and vesamicol are noncompetitive antagonists of VMAT2 and VAChT, respectively, have short durations of action, and block vesicular transport and secretion (6 -8) . Psychostimulants such as amphetamine also directly interact with VMAT2 (9, 10) and act, at least in part, by promoting release of vesicular stores of biogenic amines into the cytoplasm (11) .
VMAT2 is unique in that it is expressed on several classes of regulated secretory organelles. In most instances, biogenic amines are stored in LDCVs (120 -160 nM) together with neural peptide hormones. In noradrenergic neurons of the CNS, for instance, VMAT2 is preferentially found on LDCVs and but it is also seen on SSVs (45-50 nM) by immunoelectron microscopy (12) . In dopaminergic neurons of the substantia nigra, VMAT2 is found primarily on SSVs in axons and in tubulovesicular structures, i.e., the smooth endoplasmic reticulum, in dendrites (13, 14) . In these dendritic organelles, storage and release of dopamine is reserpine sensitive, similar to that described for the dopaminergic nerve terminals in striatum (15) . In peripheral neurons, monoamines are stored in secretory vesicles that contain markers for both SSV and LDCV membranes (16) , are intermediate in size (60 -80 nM) , and referred to as small dense core vesicles (SDCV) (17) . The different subcellular localizations of VMAT2 in various cells may be due, in part, to the types of regulated secretory organelle present in a given cell type.
Membrane proteins destined for LDCVs or SSVs differ in their trafficking from the cell body. Since LDCVs contain neuropeptide hormones, they must be produced at the trans-Golgi network (18) . SSV proteins on the other hand are thought to reach the nerve terminal via constitutive (nonregulated) vesicles (19, 20) . In peripheral neurons, VMAT2 is thought to reach the SDCV via the LDCVs (21) . A second degree of membrane trafficking occurs in the nerve terminal. There, SDCVs and SSVs can recycle via endocytosis and budding from 'early' endosomes or from an intermediate endosome-like compartment that is continuous with the plasmalemma (22) (23) (24) (25) (26) (27) .
In this study, we review work on the structure and function of the vesicular amine transporters with emphasis on the domains of the proteins that might participate in the amine/H ϩ translocation pore and be involved in differential substrate specificity. In addition, we review the evidence that the trafficking of these proteins to different secretory organelles in vitro depends on the class of organelle present in the cell and relies, in part, on information contained in their cytoplasmic tails. Since different levels of transporter expression on vesicles may affect the rate at which the vesicles are filled with transmitter and perhaps the maximal level of accumulation possible, the size of the releasable pool in vivo may not be constant (28 -30) . Thus, quantal amine secretion may depend on several factors including the intrinsic activity of the transporters, their level of expression and subcellular localization, in addition to the secretory activity of the cell.
RESIDUES IMPLICATED IN TRANSPORT FUNCTION
An understanding of the bioenergetics of vesicular transport of neurotransmitter amines has been largely derived from extensive biochemical work using bovine chromaffin granules (4, 31, 32) and SSVs isolated from the marine ray Torpedo (8) . The movement of amine substrates across membranes of secretory organelles is powered by a transmembrane electrochemical H ϩ gradient generated by the vacuolar H ϩ -ATPase. The complete transport cycle depends on the counter-transport of two protons (33, 34) . The first proton to efflux from the vesicle interior is thought to generate a high-affinity amine uptake recognition site. In the case of VMATs, this is also the reserpine binding site. Efflux of a second proton then induces a second conformational change that moves the amine across the membrane and into the vesicle. In this process, the uptake site is converted into a substrate discharge site that exhibits low affinity for substrates.
Molecular analysis of vesicular amine transporter function has enabled the testing of this model in heterologous systems. Initially, Schuldiner and coworkers identified a histidine residue in the cytoplasmic loop between TMDs 10 and 11 of VMAT1, which upon protonation is thought to induce the conformation shift that exposes the high-affinity amine binding site (35) . Aspartic acid residues that are predicted to lie in the middle of putative membranespanning domains (TMD) 1,6,10 and 11 of both VMAT1 and VMAT2 were then examined for their importance in transport function. Site-directed mutagenesis of these residues indicates that some of them play discrete roles in the transport cycle. Edwards and colleagues have shown that the aspartate in TMD 11 forms an ion pair with a conserved lysine residue in TMD 2 (36) . This interaction increases slightly the affinity of the protein for substrate but is not required for transport as the double alanine substitution retains functional activity. The salt bridge may therefore indirectly promote high-affinity substrate recognition and be important for overall structure of VMAT2 (37) . Replacement of aspartic acid residues in TMDs 1 with asparagine or alanine results in proteins that cannot catalyze the transport of 5HT (2, 37) . Reserpine binding is unaffected, indicating that the coupling to the first H ϩ and subsequent conformational change occurs. However, the ability of 5HT to displace reserpine is significantly reduced, suggesting a specific defect in substrate recognition (37) . Replacement of the aspartate in TMD 1 with glutamate reduces the maximal level of transport but does not affect the affinity for 5HT or reserpine (37) . Likewise, a negative charge in TMD 10 is essential for transport function. However, replacement of this aspartate in VMAT1 with glutamate modifies the pH profile and tetrabenazine sensitivity (38) . TMD 10 may therefore be important in steps after ligand recognition and coupling to the first H ϩ such as H ϩ /antiport. The aspartic acid in TMD 6 is not important for transport function (36) and may not actually reside within a membrane-spanning domain. Together, these studies suggest that the aspartic acid residues in TMD 1 and 10 bind protonated substrates and protons to facilitate their exchange across the vesicle membrane.
VAChT contains an additional conserved aspartic acid in the fourth TMD. Hersh and co-workers have recently reported that aspartate residues in TMD 1 and TMD 4 of VAChT do not participate in transport of ACh into synaptic-like microvesicles when transiently expressed in PC12 cells (39) . We have confirmed these results with alanine replacement of these residues in human VAChT using stable PC12 transformants (unpublished data). These results contrast with those obtained with VMAT2, where a negative charge in TMD 1 is essential for biogenic amine transport. They are also at odds with the work of Song et al. (29) , which suggests that the aspartic acid residue found in TMD 4 of VAChT is essential for transport function. Microinjection of rat VAChT in Xenopus embryos results in a significant increase in miniature end-plate currents at neuromuscular junctions that was not observed when TMD 4 aspartate of rat VAChT was changed to asparagine. Hersh and co-workers propose that this discrepancy may indicate a novel role of this aspartate in mediating ACh release (39) . Although neither aspartate residues in TMD 1 and 4 of VAChT alone are required for ACh transport, when both are replaced with alanine the affinity of VAChT for ACh and vesamicol decreases dramatically (Zhu et al., unpublished results). This indicates that these aspartate residues are in fact necessary for ACh transport, and having two may simply be redundant in VAChT. That is, the additional aspartate residue found in VAChT compared to the VMAT isoforms may have evolved in an attempt to increase the low-affinity VAChT displays for ACh (K m ϳ1 mM compared to M range for VMATs) or the efficiency of transport compared to VMAT1 and 2. The role of TMD 1 in the ACh transport function of VAChT is further supported by chimeric analysis in which a decreased affinity for ACh is observed when TMD1 of VMAT2 is present (40) . As VAChT and the VMAT isoforms share similar structure and function, it would not be surprising that TMDs 1 and 10 serve similar roles in amine/H ϩ exchange.
DOMAINS IMPORTANT FOR SUBSTRATE SPECIFICITY
VMAT2 displays higher affinity for most substrates than VMAT1. VMAT2 displays approximately two-to fourfold greater affinity for the biogenic amines 5HT, dopamine, norepinephrine, and epinephrine, and substituted aromatic amines such as methylenedioxymethamphetamine (also known as 'ecstasy'). Unsubstituted aromatic amines such as amphetamine, phenylethylamine, and histamine, however, are not good substrates for VMAT1. The affinity of VMAT1 for these amines is reduced ϳ10-to 20-fold compared to VMAT2. VMAT2 displays similar affinity for these substrates as it does for 5HT, except that histamine is ϳ10-fold lower (9, 10, 41). Edwards and colleagues have mutated numerous residues in VMAT2 in an effort to decrease highaffinity recognition of 5HT, histamine, and tetrabenazine to that displayed by VMAT1. They have concluded that multiple residues contribute to the interaction of VMAT2 with ligands (42, 43) . These studies have suggested that tyrosine-434 in TMD 11 of rat VMAT2 interacts with the hydroxyl group of 5HT. Previously, it was thought that the hydroxyl groups on the catechol or indole ring interact with a group of serines in the third TMD (37) . Whereas many mutations decrease the apparent affinity of VMAT2 for 5HT, histamine, and tetrabenazine, introduction of these residues from VMAT2 into the equivalent positions of VMAT1 does not confer high-affinity recognition of ligands (43) . It is therefore difficult to determine whether these residues interact directly with the substrate or whether they exert an indirect effect on protein structure.
A chimeric approach to determine the basis for the substrate specificity of VMAT1 and VMAT2 may also yield information regarding the putative TMDs involved in the translocation of amine substrates across the vesicle membrane. Simple chimeric transport proteins were first constructed between rat VMAT1 and VMAT2, and it was determined that two domains (TMDs 5-8 and 9 -12) are apparently both required for high-affinity interaction of ligands with VMAT2 (44). We followed this approach and have constructed a series of double chimeric transport proteins between human VMAT1 and VMAT2 in an effort to localize VMAT2 TMDs that confer highaffinity substrate recognition. We had shown previously that a chimera (2/1/2) in which the region containing half of TMD6 through TMD 10 of VMAT2 is replaced with VMAT1 sequences is important for histamine recognition (45) . This chimera retains high-affinity recognition of amphetamine, indicating that discrete domains of VMAT2 are important for the interaction of histamine and other unsubstituted aromatic amines.
Even though histamine is a relatively poor substrate for VMAT2 compared to amphetamine, it too is competitive with 5HT for transport. When expressed in permeabilized fibroblasts, VMAT1 and VMAT2 display affinities for histamine that are ϳ1 mM and 95 M, respectively, at pH 8. Thus, VMAT2 shows approximately a 10-fold greater affinity for histamine than VMAT1. Using these uptake conditions, we have further localized the domain important for histamine recognition to the region containing half of TMD6 to the beginning of TMD8. Again, this chimera retains highaffinity recognition of phenylethylamine and tetrabenazine similar to VMAT2. The corresponding 1/2/1 chimera does not display high-affinity histamine recognition, which means that other regions of VMAT2 are important as well. Preliminary observations suggest that a 2/1/2 chimera in which the 11th TMD of VMAT1 is present in VMAT2 display reduced affinity toward histamine similar to VMAT1 (Yao et al., unpublished results). In agreement with earlier studies, it is likely that multiple TMDs interact to form substrate binding sites and that differential sensitivity to unsubstituted aromatic amines, such as histamine and amphetamine relies on unique differences within different TMDs. Chimeric molecules where individual TMDs are swapped may ultimately yield a 'gain of function' phenotype for VMAT1, similar to VMAT2, and provide conclusive information as to the domains comprising the amine translocation pore.
TARGETING IN FIBROBLASTS
The transport properties of VMAT1 and VMAT2 have been determined in transfected fibroblastic CHO or CV-1 cells using membrane vesicle preparations or digitonin-permeabilized cultures (46, 47) . The ability of fibroblasts to support transport of biogenic amines and the energetic requirement of this process indicates that these transporters are targeted to intracellular compartments that contain an electrogenic vacuolar type H ϩ pump. Whereas studies of VAChT transport properties are usually determined in transfected PC12 cells (28) , like the VMAT isoforms it is also targeted to the endosomal compartment in fibroblasts (48) .
TARGETING IN NEUROENDOCRINE PC12 CELLS
The rat pheochromocytoma cell line (PC12) contains two classes of regulated secretory organelles that store different classical neurotransmitters; LDCVs contain the biogenic amine dopamine and synaptic-like microvesicles (SLMV) accumulate ACh (49) . SLMVs in PC12 cells are thought to be the neuroendocrine equivalent of cholinergic SSVs. Since VMAT2 is found on both LDCVs and SSVs in CNS neurons, several groups have questioned whether VMAT2 might be targeted to both LDCVs and the SLMVs in stably transfected PC12 cells. By immunoelectron microscopy, VMAT2 is found exclusively on LDCVs in PC12 cells differentiated with nerve growth factor (50, 51) . Western blot analysis of subcellular fractions from sucrose equilibrium density gradients of homogenates of VMAT2-expressing cells indicates that VMAT2 is found in heavy fractions containing VMAT1 and chromogranin B, markers of LDCVs and absent in lighter fractions containing synaptophysin (p38), a marker of SSVs (51) . VMAT2 is targeted to LDCVs, similarly to the endogenous expression of the endocrine-specific VMAT1 isoform, and VAChT is preferentially targeted to SLMVs in PC12 cells, similarly to the endogenous expression of the rat VAChT protein (50 -52). Thus, VMATs appear to be excluded from SLMVs of PC12 cells.
When VAChT is overexpressed in PC12 cells, it can be detected on LDCVs (48, 51) . However, the endogenous VAChT protein is rarely detected on LDCVs in control PC12 cells (50, 53) and is predominantly on SSVs in cholinergic axon terminals in situ (54) . It has been hypothesized that VAChT travels from the cell body to the nerve ending via an LDCV (2, 3). In autonomic postganglionic sympathetic cholinergic fibers, however, vasoactive intestinal polypeptide is present in rather large granular structures whereas VAChT is present mostly in small vesicles (55) . Based on studies with transfected PC12 cells, it has been purported that phosphorylation-dependent trafficking of VAChT to LDCVs may endow LDCVs with the ability to accumulate and release ACh (56) . In central cholinergic nerves and those of Torpedo, SSVs far outnumber LDCVs, in contrast to the situation in PC 12 cells, where LDCVs predominate. Furthermore, ACh and vasoactive intestinal polypeptide can selectively be released after stimulation of peripheral cholinergic nerves innervating the myenteric plexus (57) . This differential release depends on the two secretory organelles having different content and differential responsiveness to stimulation. Furthermore, this requires efficient sorting of VAChT only to SSVs. It is possible that phosphorylated VAChT exits the trans-Golgi via an LDCV in PC12 and is then dephosphorylated in the nerve terminal allowing it to reach the SMLV compartment.
Since VMAT2 is expressed on LDCVs and not on SSVs in PC12 cells, cholinergic and monoaminergic small vesicles may be fundamentally different and have unique biosynthetic origins. In peripheral noradrenergic nerves, once the LDCVs reach the nerve ending and release their content by exocytosis, the membrane proteins are able to recycle and SDCVs are formed (21, 58) . Secretagogue-triggered transfer of membrane proteins from LDCVs to SLMVs has been shown in PC12 cells (59) . These studies examined the trafficking of P-selectin, a protein that is targeted to both the LDCV and the SLMV when transfected in PC12 cells. To determine whether VMAT2 might also be transferred to SLMVs after activation of the LDCV recycling pathway, stable VMAT2-expressing PC12 cells were treated with 10 mM carbachol for 10 min at 37°C in the presence of DMEM, washed, and incubated in medium without carbachol for 30 min prior to harvesting. SLMVs were then purified by glycerol velocity centrifugation (60) and assayed by Western blotting and 3 H-TBZ binding. Neither an increase in VMAT2 immunoreactivity nor an increase in the binding of 3 H-TBZ was observed in fractions that were positive for synaptophysin after carbachol stimulation (unpublished observation). These results indicate that VMAT2 does not recycle in the SSV pathway in transfected PC12 cells and suggest that it is specifically retrieved to LDCVs (via the trans-Golgi network) after its appearance at the plasma membrane. (62), and synaptophysin, a marker of SSVs. When VMAT2 is assayed by Western blots, a predominant labeling is seen in light fractions positive for synaptophysin and synaptotagmin. This situation is clearly different than that observed with VMAT2-expressing PC12 cells (51) . Thus, the lack of monoaminergic SSVs (or SDCVs) in PC12 cells could be explained by the absence from PC12 cells of additional proteins or factors present in CAD cells that allow VMAT2 to reach the SSV compartment or allow the biogenesis of a specific subpopulation of 'noradrenergic' SSVs.
TARGETING IN NEURONAL CAD CELLS

DOMAINS IMPORTANT FOR TARGETING TO SECRETORY ORGANELLES
Recently, we have shown that when VMAT2 is engineered to contain the cytoplasmic tail of VAChT, it is targeted to SLMVs in PC12 cells, similarly to VAChT (51) . In contrast, a VAChT chimera that contains the cytoplasmic tail of hVMAT2 is relatively excluded from the SLMVs in PC12 cells. Thus, the cytoplasmic tails of the vesicular transporters contain information that allows or restricts the expression of VAChT and VMAT2 on recycling SLMVs in PC12 cells. It is not known whether the cytoplasmic tails of these proteins are necessary or even sufficient for SSV targeting in neuronal cell lines or in vivo. Since many sorting decisions are made during the transit from the Golgi stacks, in endosomal compartments and during recycling, additional cytoplasmic regions likely play important roles as well. Deletions of the cytoplasmic COOH terminus of VMAT2 have been examined to determine whether a domain within it is required for small secretory vesicle targeting in the neuronal CAD cell line (unpublished observations). For these studies, VMAT2 contains a myc epitope tag inserted into the large lumenal loop between TMD 1 and 2 that does not interfere with transport activity or subcellular localization in CAD cells. Transient expression of various carboxyl-terminal VMAT2 truncations in undifferentiated CAD cells and visualization under epifluorescence microscopy revealed no differences in the punctate pattern of distribution except when the 13 amino acids in the cytoplasmic tail of VMAT2 closest to the 12th TMD are deleted. Within these amino acids is a highly conserved KEEKMAIL sequence that is found in both VMAT isoforms in bovine, rat, and human proteins. When this region is deleted, accumulation of VMAT2 at the plasma membrane is observed and the punctate pattern of fluorescence is lost. Recently, it has been shown that the isoleucine-leucine pair within this KEEKMAIL sequence of VMAT2 functions as a signal for endocytosis (63) . In these studies, VMAT2 constructs were transfected into fibroblasts as well as neuroendocrine PC12 cells. Our results in neuronal CAD cells support these observations. Dileucinebased internalization signals in many membrane proteins are recognized by clathrin adaptor proteins AP-1, 2, and 3 (64) . Selective sorting of vesicular proteins may require AP3 (27, 65, 66) . Since the sequences immediately preceding the leucine-based endocytosis signals of VAChT and VMAT2 are highly conserved across various species, these differences may contribute to a selective interaction with APs and therefore to differences in trafficking of these proteins within the secretory pathway.
Recently, it has been shown that VAChT is phosphoryated by protein kinase C (67) and that the residue responsible (serine; 480) lies in the cytoplasmic tail (56, 68) . This serine is located 5 amino acids upstream of a dileucine motif in VAChT. VMAT2 has two glutamic acid residues (E478/E479) at the corresponding position, which is located 5 amino acids upstream of the isoleucine-leucine pair. These dileucine-like pairs may be important for efficiency of endocytosis (63) . Using a transient expression system, Hersh and co-workers demonstrate that mutation of serine (480) to alanine shifts the localization of immunoreactivity in sucrose density gradients to fractions intermediate of those containing synaptophysin and secretogranin II, indicating that phosphorylation of VAChT is required for SMLV targeting in PC12 cells (68) . In the stably transfected PC12 lines of Edwards and colleagues, however, neither the serine (180) to alanine mutation nor the serine (180) to glutamate mutation affect the relative level of targeting of VAChT to SMLVs (56) . Instead, these mutations in VAChT, as well as the double glutamate (E478A/E479A) to alanine mutation in the cytoplas-mic tail of VMAT2 appear, to some degree, to affect the relative amounts of these proteins on LDCVs (56) .
VESICULAR TRANSPORT ACTIVITY, STORAGE AND QUANTAL SECRETION
While it is generally assumed that the size of a quantum is fixed for a given neurotransmitter, recent evidence indicates that the amount of transmitter accumulated in synaptic vesicles can be altered, thereby affecting the amount of transmitter available for release from neurons. Maximal vesicular accumulation and the speed at which vesicles are filled may depend on transmitter synthesis and catabolism, the intrinsic activity or level of expression of the transporter, and during periods of high neuronal activity, the rate of SSV recycling.
The cytoplasmic concentration of transmitter available for sequestration is an important determinant for the level of vesicular storage and amount available for secretion. The levels of dopamine (0.5-2 M) and ACh (0.2-1 mM) in the cytoplasm are around the half-maximal substrate concentrations for their respective transporters (8, 69) . Thus, changes in biosynthesis or degradation of these transmitters could affect the rate that vesicles could fill and the levels attained at equilibrium. Sulzer and co-workers have shown in tissue culture that the number of dopamine molecules per quantum released from LDCVs (in PC12 cells) and SSVs (in midbrain dopamine neurons) increases severalfold after exposure to the dopamine precursor L-dihydroxyphenylalanine (70) . Similar effects are seen in cholinergic systems in vitro and in vivo, where administration of choline is rapidly accumulated by cholinergic neurons, enhancing both the biosynthesis and release of ACh (71) (72) . Furthermore, genetic mutants of choline acetyltransferase in nematodes and flies that have reduced enzyme activity exhibit behavioral phenotypes consistent with reduced cholinergic neurotransmission (73, 74) .
Alterations in the molecular structures that determine intrinsic activity, such as the substrate affinity or the efficiency of transport (V max /K m ), also affect vesicular accumulation of transmitter and subsequent regulated neurotransmitter release. Rand and colleagues have assembled a collection of unc-17 point mutants that express normal amounts of VAChT on SSVs but show resistance to esterase inhibition and exhibit behavior changes consistent with a deficit in ACh neurotransmission (75) . Expression of the corresponding mutant VAChT proteins in a heterologous system has revealed that several display reduced affinity for ACh, indicating that the mutations were in TMDs directly involved in ACh recognition (unpublished data). Others are in regions that affect V max only or the binding of vesamicol, and may be important in steps of the ACh transport cycle beyond substrate recognition such as H ϩ exchange. These results indicate that specific structural changes in VAChT can be correlated with specific alterations in the biochemical parameters of transport, neurosecretion, and behavioral severity of the cholinergic deficit.
The level of expression of the vesicular transporters in whole organisms and in transfected cells is yet another way to influence the amount of transmitter stored in each synaptic vesicle and therefore the amount released from neurons. Heterozygotic VMAT2 knockout mice display a 50% decrease in protein expression, which results in corresponding decreases in vesicular transport activity and quantal release (30) . In heterozygotic VAChT knockout flies, a 50% decrease causes an abnormality in cholinergic transmission when stressed by a high-frequency stimulus (76) . Overexpression of VAChT in PC12 cells and in Xenopus embryos increases ACh accumulation in SSVs and quantal size by two-to threefold (28, 29) . Different levels of transporter expression on synaptic vesicles may account for the heterogeneity of transmitter storage and release observed in several systems (77) (78) (79) (80) .
FUTURE PERSPECTIVES
Identification of the molecular structures of the vesicular amine transporters that determine substrate specificity and trafficking within the secretory pathway are two important avenues of research that will enable a better understanding of the differences in function and evolution of presynaptic monoaminergic and cholinergic synapses. The further analysis of chimeric molecules yielding 'gain of function' phenotypes as well as the exploitation of genetic approaches in C. elegans and Drosophila may ultimately enable the identification of the TMDs and amino acids that participate in the amine/H ϩ translocation pore. The use of primary neuronal cultures or genetic 'knock in' experiments of vesicular transporter targeting within the secretory pathway may alleviate the potential problems of cell background found using heterologous systems. Regulation of the intrinsic activity (81) (82) (83) of the vesicular transporters is a relatively unexplored area, but recent data suggest that it may be a general feature of monoaminergic neurons that controls the content of both LDCVs and SSVs (82) . Evidence that ACh storage and release can be modified by protein kinases suggests that VAChT might be regulated at the level of vesicular transport or targeting to secretory organelles (83) (84) (85) (86) . VAChT is phosphorylated in rat brain synaptosomes and in PC12 cells by protein kinase C (56, 67, 68). VMAT2 is also phosphorylated by casein kinase II (87) . Whether phosphorylation modulates intrinsic activity and/or regulates trafficking to secretory organelles, the rate at which vesicles accumulate transmitter, and the amount of transmitter released on neurosecretion may be altered. Identifying potential sites for regulation of vesicular amine transport function may therefore be important during development of cholinergic and monoaminergic synapses and an important mechanism for synaptic plasticity.
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